A phase I open-label, dose-escalation trial to evaluate the safety, pharmacokinetics, and pharmacodynamics of MGCD0103 (MG 0103) in combination with docetaxel (Taxotere) in subjects with advanced solid malignancies

Trial Profile

A phase I open-label, dose-escalation trial to evaluate the safety, pharmacokinetics, and pharmacodynamics of MGCD0103 (MG 0103) in combination with docetaxel (Taxotere) in subjects with advanced solid malignancies

Discontinued
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2015

At a glance

  • Drugs Docetaxel; Mocetinostat
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors MethylGene; Mirati Therapeutics; Pharmion Corporation
  • Most Recent Events

    • 03 Dec 2008 Status changed from suspended to discontinued, based on information from ClinicalTrials.gov. This Celgene sponsored trial was closed following terminiation of the collaborative agreement between Celgene and MethylGene (for the development of MGCD0103).
    • 22 Sep 2008 Celgene Corporation reported as a company Affiliate and Sponsor by ClinicalTrials.gov.
    • 22 Jul 2008 Status changed from recruiting to in progress based on information from ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top